

June 25, 2014


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (BC-51)	GILTERITINIB
PRONUNCIATION	gil" te ri' ti nib
THERAPEUTIC CLAIM	Treatment of acute myeloid leukemia

CHEMICAL NAMES

1. 2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2*H*-pyran-4-yl)amino]-
2. 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-[(tetrahydro-2*H*-pyran-4-yl)amino]pyrazine-2-carboxamide
3. 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-(oxan-4-ylamino)pyrazine-2-carboxamide

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₂₉ H ₄₄ N ₈ O ₃
MOLECULAR WEIGHT	552.7
TRADEMARK	None as yet
SPONSOR	Astellas Pharma Global Development Inc.
CODE DESIGNATIONS	ASP2215
<u>CAS</u> REGISTRY NUMBER	1254053-43-4
UNII	66D92MGC8M
WHO NUMBER	10048

gbk